Insulet (NASDAQ:PODD) announced Friday that its tubeless insulin delivery system, Omnipod 5, performed better than conventional insulin pumps in a clinical trial for patients with type 1 diabetes. Its ...
Insulet is disrupting how patients can treat their diabetes, capitalizing on its differentiated Omnipod on-the-body delivery technology, CEO Jim Hollingshead explains to Bloomberg Intelligence. In ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results